Iovance Biotherapeutics, INC Schedule 13G passive stakes

State Street Corporation has reported a beneficial ownership of 5.5% in Iovance Biotherapeutics Inc. through a Schedule 13G filing.

State Street Corporation has reported a beneficial ownership of 4.2% in Iovance Biotherapeutics Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership stake in Iovance Biotherapeutics Inc. following an internal corporate realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in Iovance Biotherapeutics Inc., holding over 20 million common shares as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 7.50% beneficial ownership stake in Iovance Biotherapeutics Inc., totaling 25,076,472 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in Iovance Biotherapeutics, Inc. as of June 30, 2025.

Perceptive Advisors and its affiliates have reported a decrease in their beneficial ownership of Iovance Biotherapeutics, Inc. common stock to 3.8%, falling below the 5% threshold.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported a continued beneficial ownership of 7.3% in Iovance Biotherapeutics, Inc., holding 22,112,266 shares as of December 31, 2024.